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Introduction 
 
Lipocalin-2 [also known as 24p3, neutrophil 
gelatinase-associated lipocalin and siderocalin] 
belongs to the diversified lipocalin family that 
generally binds small hydrophobic ligands [1-3]. 
It is a 25-kDa adipokine constitutively produced 
by adipocytes [4-7]. The expression of lipocalin-
2 is upregulated in pathological conditions such 
as obesity, inflammation, hypertension and 
cancer [8-10]. Abnormal regulation and func-
tion of lipocalin-2 contribute to the develop-
ment of obesity-related medical complications 
[11-16]. Recent evidences suggest that lipo-
calin-2 can be used as a diagnostic and prog-
nostic marker for overt heart disease [17]. Cir-
culating levels of lipocalin-2 are augmented 
and correlated closely with the severity of coro-
nary heart disease [18, 19]. It is a biomarker 
for early detection of cardio-renal syndrome in 
patients with acute heart failure [20]. During 
systemic adaptation to chronic heart failure, 
patients with baseline lipocalin-2 > 783 ng/ml 
have a significantly higher mortality [21]. In 
both human and rodents, increased expression 
of lipocalin-2 is found in necrotic areas and the 
surrounding tissue of the infarcted heart [17, 
22-24]. Results derived from animal studies 
suggest that lipocalin-2 may be actively in-
volved in modulating the heart functions in re-
sponse to acute injuries [23, 25, 26]. On the 
other hand, there is no information available 
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Abstract: Aims: Recent clinical and experimental evidences demonstrate an association between augmented circulat-
ing lipocalin-2 [a pro-inflammatory adipokine] and cardiac dysfunction. However, little is known about the pathophysi-
ological role of lipocalin-2 in heart. The present study was designed to compare the heart functions of mice with nor-
mal (WT) or deficient lipocalin-2 (Lcn2-KO) expression. Methods and results: Echocardiographic analysis revealed that 
the myocardial contractile function was significantly improved in hearts of Lcn2-KO mice, under both standard chow 
and high fat diet conditions. The heart function before and after I/R injury (20-min of global ischemia followed by 60-
min of reperfusion) was assessed using the Langendorff perfusion system. Compared to WT littermates, hearts from 
Lcn2-KO mice showed improved functional recovery and reduced infarct size following I/R. Under baseline condition, 
the mitochondrial function of Lcn2-KO hearts was significantly enhanced, as demonstrated by biochemical analysis of 
respiratory chain activity and markers of biogenesis, as well as electron microscopic investigation of the mitochon-
drial ultrastructure. Acute or chronic administration of lipocalin-2 impaired cardiac functional recovery to I/R and 
dampened the mitochondrial function in hearts of Lcn2-KO mice. These effects were associated with an extensive 
modification of the fatty acyl chain compositions of intracellular phospholipids. For example, lipocalin-2 facilitated the 
redistribution of linoleic acid (C18:2) among different types of phospholipids, including cardiolipin, a structurally 
unique phospholipid located mainly on the inner membrane of mitochondria. Conclusions: Lack of lipocalin-2 im-
proved the functional recovery of isolated mice hearts subjected to I/R, which is associated with restoration of mito-
chondrial function and phospholipids remodeling.  
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regarding the effects of this protein on cardiac 
contractile and hemodynamic functions.  
 
The present study evaluated the heart func-
tions of mice lacking lipocalin-2 at both base-
line condition and in response to I/R injury. The 
results demonstrated that the presence or ab-
sence of lipocalin-2 could modulate cardiac 
performance and functional recovery to I/R. 
Mice without lipocalin-2 showed a better con-
tractile activity and were partially protected 
from I/R-induced injury. The mitochondrial func-
tion was significantly improved in the heart tis-
sues of lipocalin-2 knockout mice. Replace-
ment with lipocalin-2 adversely modified the 
heart function and promoted remodeling of 
intracellular phospholipids. These findings col-
lectively support a role of lipocalin-2 in the 
pathogenesis of heart diseases, especially un-
der conditions such as obesity, metabolic syn-
drome and aging. 
 
Materials and methods 
 
Animals 
 
All the animal experimental procedures were 
approved by the Committee on the Use of Live 
Animals for Teaching and Research, the Univer-
sity of Hong Kong (1852-09), and carried out in 
accordance with the Guide for the Care and 
Use of Laboratory Animals published by the US 
National Institutes of Health (NIH publication 
no. 85-23, revised 1996). Male wild type (WT) 
and Lcn2-KO mice of C57BL/6J background 
were randomized to receive a high-fat diet 
[D12451, 4.65 kcal/g, 23.6% fat from primarily 
lard composed of 45% of the caloric intake 
(Research Diet, New Brunswick, NJ, USA)] or a 
standard chow [LabDiet 5053, 3.41 kcal/g, 
13.2% fats (Purina Mills Inc., Richmond, IN, 
USA)] from the age of four weeks onwards [12, 
16]. Chronic treatment was performed by tail 
vein injection of the adenovirus encoding a 
FLAG-tagged murine lipocalin-2, while acute 
treatment was achieved by intraperitoneal in-
jection of the murine lipocalin-2 recombinant 
protein [12, 16].  
 
Evaluation of cardiac function 
 
Echocardiographic studies were performed un-
der light anesthesia with the use of intraperito-
neal ketamine (100 mg/kg) and xylazine (1.25 
mg/kg). A Vivid i cardiovascular ultrasound sys-
tem with a 11.5 MHz probe (GE Healthcare, 
Milwaukee, WI) was used for echocardiographic 
examination. For Langendorff perfusion, mice 
were anaesthetized with an intraperitoneal (i.p.) 
injection of a mixture of fluanisonum (25 mg kg
–1) and fentanylum (0.78 mg kg–1) (Hypnorm®, 
Janssen Pharmaceutica, Beerse, Belgium) and 
midazolam (12.5 mg kg–1) (Dormicum®, Hoff-
man-La Roche, Basel, Switzerland). Loss of con-
sciousness and suppression of reflexes 
(withdrawal reflex and tail pinch response ab-
sent; limb muscle tone absent; heart and respi-
ratory rates regular) were checked to ensure 
the animal is anesthetized deeply enough. The 
hearts were excised, aorta cannulated and ret-
rograde perfusion initiated immediately at a 
constant perfusion pressure of 80 mmHg. A 
polyethylene, fluid-filled balloon was introduced 
into the left ventricle (LV) cavity for assessing 
contractile functions. Global ischemia was 
achieved by clamping the inflow tubing. The 
isolated hearts were subjected to either con-
tinuous perfusion for 80 min or a period of 20 
min global ischemia followed by 60 min or 120 
min (for infarct size analysis) of reperfusion. 
The left ventricular systolic pressure (LVSP), left 
ventricular end diastolic pressure (LVEDP), 
heart rate (HR) and coronary flow (CF) were 
monitored continuously. Effluent from the per-
fused heart was collected for measuring lactate 
dehydrogenase (LDH) activity. After perfusion, 
the hearts slices stained with 2,3,5-triphenyl-
tetrazolium chloride were analyzed for LV area 
and infarct area (IA) using Image J software 
(National Institutes of Health). The infarct size 
was expressed as a percentage of the total LV 
area [27]. 
 
Measurement of mitochondrial respiratory 
chain (MRC) activities 
 
The mitochondria were isolated from freshly 
collected heart tissues by following the instruc-
tion of a commercial kit MITOISO1 (Sigma, St 
Louis, MO, USA). The MRC activity of individual 
complex was evaluated by biochemical assays 
[28]. The mitochondrial ultrastructure and DNA 
copy number was evaluated as previously de-
scribed [28]. 
 
Extraction and fractionation of cardiac phos-
pholipids 
 
Total lipids were extracted from heart tissue by 
a modified Folch method [12, 28]. Solid phase 
extraction was performed for phospholipids 
fractionation using the aminopropyl bond col-
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umn (Waters Milford, MA, USA) [29]. In brief, 1 
ml chloroform/methanol (2:1, v/v) was added 
to 200 μl tissue lysates and the lower organic 
phase was collected. The organic solvents were 
evaporated by blowing nitrogen to reduce the 
volume to ~100 μl. The column was equili-
brated with 1 ml hexane. Subsequently, the 
total lipid extract was applied to the column 
under moderate vacuum. Neutral lipids and 
free fatty acids were eluted with chloroform/
isopropanol (2:1, v/v) and acetic acid/diethyl 
ether (2:98, v/v), respectively. In sequence, 
phosphatidylcholine (PC) was eluted with ace-
tonitrile/n-propanol (2:1, v/v), followed by the 
elution of phosphatidylethanolamine (PE) and 
phosphatidylserine (PS), using methanol and 
isopropanol/3N HCl in methanol (4:1, v/v), re-
spectively. Finally, phosphatidylinositol (PI) was 
eluted with methanol/3N HCl in methanol (9:1, 
v/v). Each fraction of the phospholipids was 
subjected to fatty acyl chain composition analy-
sis by gas chromatography-mass spectrometry 
(GC-MS) as previously described [12]. For mito-
chondrial samples, phospholipids were ex-
tracted as above and all four fractions (PC, PE, 
PS and PI) were combined for GC-MS analysis. 
The results were normalized against the initial 
protein content in each sample. 
 
Separation and comparison of cardiolipin con-
tents using high-pressure liquid chromatogra-
phy (HPLC) 
 
Cardiolipin phospholipids fractions were pre-
pared from isolated mitochondria (1.5 mg) as 
described [30]. After sequential extraction, 
phospholipids enriched with cardiolipin were 
eluted with methanol, evaporated under nitro-
gen flow and reconstituted in 150 μl methanol. 
Fifty microliters of the resulting sample were 
used for reversed-phase HPLC separation, 
which was performed on a Symmetry® C18 col-
umn (5 μm, 3.9 × 150 mm, Waters) with the 
mobile phase consisted of solvent A [methanol-
acetonitril-0.01M KH2PO4/KOH (pH 7.5, 3:6:1, 
v/v/v)] and solvent B [methanol-acetonitrile 
(2/3)]. Chromatographic peaks detected by UV 
at 205 nm were collected for subsequent analy-
sis of acyl-group composition. Cardiolipin stan-
dard (5.3 mg/mL in ethanol, ≥ 98%, Sigma) 
was used for comparison and quantification.  
 
Data analysis 
 
All results were derived from at least three sets 
of repeated experiments. The statistical calcu-
lations were performed by Student’s t-test and 
one-way analysis of variances followed by Tukey 
multiple comparisons using Prism version 5 
(GraphPad Software; San Diego, CA, USA). All 
values are presented as means ± SEM. In all 
statistical comparisons, a P value less than 
0.05 was considered to indicate significant dif-
ferences. 
 
Results 
 
Lipocalin-2 deficiency improved the recovery of 
heart functions during ischemia/reperfusion (I/
R) injury 
 
Hearts collected from WT and Lcn2-KO mice 
displayed no overt abnormalities and the ratios 
of heart/body weight were similar 
(Supplementary Table 1). Echocardiography 
analysis revealed no significant differences of 
the systolic/diastolic LV posterior wall thickness 
(LVPW) and interventricular septum (IVS) thick-
ness between the two groups of mice under 
both standard chow and high fat diet condi-
tions. Compared to the values of WT mice, the 
percent LV ejection fraction (EF) and the per-
cent LV fractional shortening (FS) of Lcn2-KO 
mice were elevated slightly but significantly by 
~9% and ~15%, respectively (Supplementary 
Table 1). Next, the function of hearts isolated 
from high fat diet fed animals was evaluated by 
applying an acute global I/R injury with the use 
of Langendorff perfusion system. At the end of 
the equilibration period, LVDP was 99.4 ± 2.0 
and 102.1 ± 4.5 mmHg, RPP was 361.9 ± 14.2 
and 370.9 ± 13.5 mmHg/min/100 , CF was 
4.5 ± 0.2 and 4.4 ± 0.5 ml/min and the aver-
age HR was 363.8 ± 10.5 and 363.3 ± 16.1 
beats/min, for the hearts from WT and Lcn2-KO 
mice, respectively. Compared to those of the 
WT mice, post-ischemic recovery of LVDP and 
RPP was significantly improved in hearts iso-
lated from Lcn2-KO mice (Figure 1A and 1B), 
whereas the recovery of CF and HR was not 
different between the two groups (data not 
shown). LVEDP increased during no flow global 
ischemia and decreased to 4-10 mmHg after 
reperfusion in both WT and Lcn2-KO hearts, 
suggesting that the systolic function might be 
different between the two groups of hearts. In 
addition to these observations, the release of 
LDH, an injury marker of myocardial infarction, 
and the ratio of infarct sizes (IA/LV) was signifi-
cantly reduced in Lcn2-KO hearts (Figure 1C 
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and 1D).  
 
Mitochondrial functions were significantly en-
hanced in hearts of Lcn2-KO mice 
 
Electron microscopy was applied to evaluate 
the ultrastructures of hearts in WT and Lcn2-KO 
mice. As shown in Figure 2A, the alignments 
and morphology of interfibrillar mitochondria 
were markedly different between the two 
groups of hearts collected from mice fed with 
high fat diet for seven weeks. In WT hearts, the 
density of mitochondria significantly increased. 
There were small distinct crystalline or dense 
particles in the mitochondrial matrix. The aggre-
gates of mitochondria disrupted myofibril ar-
rays. In Lcn2-KO hearts, the interfibrillar mito-
chondria were arranged parallel to the myofi-
brils in a more stereotypic manner. The cristae 
area was much higher in Lcn2-KO hearts and 
no vacuoles could be observed in the matrix. To 
further evaluate the mitochondrial function, 
biochemical measurement of MRC activities 
was performed using the total mitochondria 
isolated from heart tissues of mice fed with a 
high fat diet for seven weeks (Figure 2B). The 
yield from Lcn2-KO hearts was slightly higher 
(46.37 ± 1.82 mg/g) than that from WT mice 
hearts (41.19 ± 3.04 mg/g). Compared to 
those of the WT hearts, the activities of com-
plex I, II+III, IV and complex V of Lcn2-KO hearts 
were significantly increased by 26.94%, 
162.39%, 43.50% and 60.02%, respectively. 
The copy number of mitochondria mtDNA was 
not significantly different between the two 
groups of hearts, although the expression of 
genes involved in mitochondrial biogenesis 
were elevated in the heart tissues of Lcn2-KO 
mice (Supplementary Figure 1).  
 
Treatment with lipocalin-2 attenuated heart 
performances during I/R injury  
 
Lcn2-KO mice were treated with recombinant 
adenovirus encoding lipocalin-2 for cardiac 
function evaluation (Figure 3A). The augmented 
circulating lipocalin-2 levels (264.53 ± 18.69 
ng/ml) were comparable to those in WT ani-
mals and lasted for over two weeks [12]. Over-
expressing lipocalin-2 significantly suppressed 
the recovery of cardiac contractile function. In 
particular, the chronic treatment decreased the 
recoveries of LVDP by 33.98% and RPP by 
47.28% at 5-min of reperfusion when compared 
to the luciferase control group. At 60-min of 
reperfusion, LVDP and RPP only recovered to 
~70% of the control group. In addition to the 
dampened responses to I/R injury, recombinant 
adenovirus-mediated chronic overexpression of 
lipocalin-2 also led to a significant reduction of 
the activity of all MRC complexes in heart tis-
sues of Lcn2-KO mice (Figure 3B). 
 
Next, the acute effects of lipocalin-2 on heart 
functional recovery during I/R injury were inves-
tigated. 800 μg recombinant lipocalin-2 protein 
Figure 1. Lipocalin-2 deficiency 
protects the heart against I/R 
injury in mice fed with high fat diet 
for 7-wk. Isolated hearts from wild 
type (WT) or Lcn2-KO mice were 
subjected to I/R injury as de-
scribed in Methods. Recovery of 
LVDP (A) and RPP (B) were re-
corded at 1, 5, 10, 20, 30 and 60 
min during reperfusion and pre-
sented as percentages of the pre-
ischemia baseline values (BSL). 
LDH was measured in the per-
fusates using a commercial kit 
(C). Myocardial infarction was 
evaluated by calculating the ratio 
of IA/LV area as described in 
Methods (D). * P < 0.05 vs WT, n 
= 10. BSL, baseline values. 
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or PBS vehicle was injected intraperitoneally 
into Lcn2-KO mice that had been fed with a 
high fat diet for seven weeks [12, 16]. Com-
pared to the circulating lipocalin-2 levels in WT 
mice (202.49 ± 21.07 ng/ml), those in Lcn2-KO 
mice were augmented by 10-15 folds at 1- and 
2-h after injection and dropped to the control 
levels by 6-h [12]. In isolated Lcn2-KO heart 
tissues, the protein amount was transiently 
elevated to 122.79 ± 29.89 ng/mg (similar to 
that in WT hearts, 130.39 ± 40.26 ng/mg) for a 
short period and rapidly decreased to 15.20 ± 
1.48 ng/mg at 2-h after injection. At 6-h of 
treatment, there were barely detectable levels 
of lipocalin-2 in Lcn2-KO hearts. Accordingly, 
the recovery of heart function to I/R was signifi-
cantly inhibited by lipocalin-2 treatment in a 
time-dependent manner (Figure 4). At 1-h after 
protein injection, the values of LVDP and RPP at 
5-min reperfusion were dropped by 59.61% and 
72.24%, respectively, when compared to the 
vehicle group. At the end of reperfusion period, 
LVDP and RPP only recovered to ~60% of the 
control group. Time-dependent effects of lipo-
calin-2 on LDH release could also be observed. 
These effects were diminished after 6-h of 
treatment (data not shown). Echocardiography 
analysis revealed that acute treatment with 
lipocalin-2 decreased both EF (63.00 ± 2.35 vs 
69.01 ± 3.58 of vehicle group, P < 0.05, n = 8) 
and FS (29.67 ± 2.89 vs 34.00 ± 3.68 of vehi-
cle group, P < 0.05, n = 8) of the Lcn2-KO 
hearts by ~8% and ~12%, respectively.  
 
Acute treatment with lipicalin-2 recombinant 
protein also inhibited the cardiac MRC activities 
of Lcn2-KO mice (Figure 5). As early as 1-h after 
intraperitoneal injection, a significant reduction 
of MRC activity was observed for complex II+III 
(by 35.65%), complex IV (by 23.66%) and com-
plex V (by 32.61%). Four hours after injection, 
the activity of complex IV was raised to the con-
trol level, whereas those of the other three 
complexes remained significantly low.  
 
Lipocalin-2 modulated the fatty acyl composi-
tion of cellular and mitochondrial phospholipids 
 
Figure 2. Enhanced cardiac mitochondrial 
function in Lcn2-KO mice. A, Ultra-
structure of the heart tissues from age-
matched (11-wk) wild type (WT) and Lcn2-
KO mice fed with 7-wk of high fat diet was 
analyzed using transmission electron mi-
croscopy. Sections from four hearts per 
group were examined with a minimum of 
eight fields per section. Representative 
electron photomicrographs are shown at a 
magnification of 8000x. Scale bars repre-
sent 1 μm. B, The activities of cardiac 
MRC complex I, complex II+III, complex IV 
and complex V of wild type (WT) or Lcn2-
KO mice fed with 7-wk of high fat diet were 
measured as described in Methods. * P < 
0.05 and ** P < 0.01 vs respective con-
trols, n = 8.  
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Lipocalin-2 belongs to a family of lipid carrier 
protein [2, 10]. Mice deficient with this protein 
show different free fatty acid (FFA) composition 
in adipose tissue [12]. GC-MS analysis, how-
ever, did not suggest a significant difference of 
FFA composition between the heart tissues of 
WT and Lcn2-KO mice (data not shown). On the 
other hand, the fatty acyl composition of phos-
phatidylcholine (PC), phosphatidylethanolamine 
(PE) and phosphatidylinositol (PI) was remarka-
bly different between Lcn2-KO and WT hearts 
(Supplementary Figure 2). For example, the 
percentage composition of C16:0 was signifi-
cantly higher in PI, but less in PE of WT hearts 
when compared to Lcn2-KO hearts. By contrast, 
the polyunsaturated fatty acyl compositions of 
C20:4 and C22:6 were increased in the PE frac-
tions of WT hearts. The distribution of C18:2 
acyl was shifted from PI (5.16%) in WT hearts to 
PC (5.48%) in Lcn2-KO hearts (Supplementary 
Figure 3). In addition, the fatty acyl composition 
of mitochondrial phospholipids was also signifi-
cantly different between the two groups of 
hearts (Supplementary Figure 4). Further analy-
sis of heart tissues from mice treated with vehi-
cle or lipocalin-2 revealed that C18:2 is one of 
the major fatty acyl chains regulated by lipo-
calin-2 (Figure 6). Acute treatment with this 
protein down-regulated the percentage compo-
sition of C18:2 in PC by over 20-fold and ele-
vated this fatty acyl species in PI by ~20-fold. In 
addition, the contents of C20:4 and C22:6 in PI 
and PC were altered in an opposite direction by 
the treatment (Figure 6A). The fatty acyl compo-
Figure 3. Chronic over-
expression of lipocalin-2 
suppresses cardiac func-
tional recovery during I/R 
injury and the MRC activity. 
Recombinant adenoviruses 
(108 pfu) expressing lipo-
calin-2 or luciferase were 
injected into tail vein of 
Lcn2-KO mice fed with 4-wk 
of high fat diet. Two weeks 
later, the mice were sacri-
ficed for heart function 
evaluation as in Figure 1A or 
MRC activity measurement 
as in Figure 2B. * P < 0.05 
and **, P < 0.01 vs 
luciferase group, n = 8. BSL, 
baseline.  
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sition of mitochondrial phospholipids was also 
analysed using the isolated mitochondrial frac-
tions. Lipocalin-2 significantly modified the per-
centage contents of several species by over 2-
fold, including C18:2, C20:2, C20:4 and C24:0 
(Figure 6A). Moreover, it facilitated the remodel-
ing of fatty acyl composition in cardiolipin, a 
mitochondrial inner membrane phospholipid. 
Six cardiolipin species containing different com-
binations of fatty acyl chains could be repro-
ducibly detected in mitochondria from both WT 
and Lcn2-KO hearts (Supplementary Figure 5). 
Integration analysis of the area under curve did 
not suggest a significant change of the total 
cardiolipin contents. However, compared to 
that in WT heart samples, the amount of 
(C18:2)2(C22:6)2 and (C18:2)3(C22:6)1 in Lcn2-
KO mitochondria were decreased by ~20% and 
~40%, respectively. In addition, the content of 
(C18:2)2(C18:1)1(C22:6)1 species was ~1.7 fold 
higher than that of WT mitochondria. Admini-
stration of lipocalin-2 restored all three species 
to the level of WT samples (Figure 6B).  
 
Discussion 
 
Although a potential causal relationship be-
tween lipocalin-2 and cardiac dysfunction has 
been suggested [21, 22, 24, 25, 31], limited 
information is available regarding the role of 
this adipokine in regulating cardiac contractile 
function. Using both echocardiography and Lan-
gendorff perfusion system, the present study 
demonstrates that hearts derived from mice 
without lipocalin-2 show improved LV systolic 
performance (FS and EF) and a better func-
tional recovery during I/R injury. On the con-
trary, administration of lipocalin-2 to these mice 
impaired cardiac contractile activity under both 
basal and I/R conditions. 
 
Optimal cardiac contractile function requires 
mitochondria to maintain a sufficient energy 
supply [32]. Defects in mitochondrial function 
can cause energetic alterations and compro-
mise the generation of sufficient amounts of 
ATP, in turn affecting the contractile apparatus 
and rendering the heart more susceptible to 
ischemic injury [33]. Furthermore, abnormal 
mitochondrial function increases the produc-
tion of superoxide anions from MRC complex I 
and III, which contributes to the transition from 
reversible to irreversible injury during reperfu-
sion [34]. The results of the present study dem-
onstrate that due to the improved cardiac mito-
chondrial function, lipocalin-2 deficiency par-
tially preserves myocardium from I/R injury in 
mice. Lipocalin-2 deficiency is associated with 
more organized mitochondrial ultra-structure, 
augmented cardiac MRC activity, as well as 
Figure 4. Acute administration of lipocalin-2 time-
dependently attenuates the recovery of heart func-
tion during I/R injury. After high fat diet for 7-wk, Lcn2
-KO mice were injected intraperitoneally with recombi-
nant lipocalin-2 protein as described in Methods. At 1
-, 2- and 4-h after treatment, hearts were isolated 
and subjected to 20 min of global ischemia followed 
by 60 min of reperfusion. Recovery of LVDP (A) and 
RPP (B), LDH release (C) were recorded and pre-
sented as in Figure 1. PBS was used as vehicle con-
trol, which did not affect the heart performance 
throughout the experimental period (data not shown). 
* P < 0.05 vs vehicle treatment, n = 8. BSL, baseline.  
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enhanced mitochondrial biogenesis. Replace-
ment with lipocalin-2 by both chronic overex-
pression and acute protein treatment attenu-
ates MRC activity and the functional recovery to 
I/R.  
Analysis of cellular phospholipids suggests that 
lipocalin-2 exerts its actions in heart at least in 
part by regulating specific phospholipids pools. 
In particular, those containing the linoleic acid 
(C18:2) are more sensitive to the presence or 
Figure 5. Acute treatment with lipocalin-2 
rapidly decreases cardiac MRC activity. 
Hearts were collected from Lcn2-KO mice 
treated with lipocalin-2 protein as in Fig-
ure 4. The MRC activity of different com-
plexes was evaluated by biochemical 
assays. * P < 0.05 vs vehicle controls, n 
= 8. 
 
Figure 6. Lipocalin-2 promotes 
cardiac phospholipids remodeling. 
Heart tissues were collected from 
Lcn2-KO mice treated without or 
with lipocalin-2 for 2-h as de-
scribed in Figure 4. Phospholipids 
were prepared from both tissue 
lysates and mitochondrial frac-
tions. A, Fatty acyl composition in 
different types of phospholipids, 
including PC, PI and total mito-
chondrial phospholipids, was ana-
lysed by GC-MS as described in 
Methods. The results were nor-
malized to total protein contents 
and presented as fold changes 
against vehicle group, n = 6. B, 
Reversed-phase HPLC was per-
formed for fractionation of cardi-
olipin species isolated from heart 
tissues of WT mice and Lcn2-KO 
mice treated with vehicle or lipo-
calin-2. Integration analysis of the 
area under curve was performed 
for the six species of cardiolipin. 
The results were presented as the 
percentage composition of each 
species. * P < 0.05 vs WT, n = 4.  
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absence of this protein. Lipocalin-2 modifies 
the composition of C18:2 acyl chains in the 
phospholipids sub-fractions PC and PI, as well 
as the mitochondrial inner membrane phos-
pholipids, cardiolipin, a phospholipid critically 
involved in regulating mitochondrial structure, 
oxidative phosphorylation and biogenesis [35, 
36]. Cardiolipin binding is essential for the sta-
bility of respiratory chain supercomplexes and 
oxidative generation of ATP [37]. Structurally, 
cardiolipin consists of two phosphatidyl resi-
dues linked by a glycerol moiety and attached 
with a total of four fatty acyl chains [38]. In 
mammalian hearts, cardiolipin enriched with 
symmetric linoleic acid (C18:2) provides opti-
mal function [39]. The 18-carbon unsaturated 
acyl side-chain is essential for the high affinity 
binding of cardiolipin to membrane proteins, 
and an 18:2-rich configuration is particularly 
important for maintenance of mitochondrial 
respiration [36]. The loss of linoleic acid con-
tent due to cardiolipin remodeling occurs in 
various cardiac disorders, including I/R injury, 
heart failure, diabetic cardiomyopathy and ag-
ing-induced cardiac dysfunction [40-42]. Here, 
the results demonstrate that in Lcn2-KO mice 
hearts, the contents of linoleic acid (C18:2) in 
mitochondria are elevated when compared to 
WT hearts. Moreover, lipocalin-2 modulates the 
fatty acyl compositions of non-symmetric cardi-
olipin species, especially those containing both 
C18:2 and C22:6 fatty acyl chains. By promot-
ing the fatty acyl remodeling of cardiolipin spe-
cies, lipocalin-2 may adversely affect mitochon-
drial function and energy production, hence 
impairing cardiac performances during I/R in-
jury.  
 
Lipocalin-2 also alters the intracellular distribu-
tion of other fatty acyl, such as C20:4 and 
C22:6. The release of arachidonic acid (AA, 
C20:4) from phospholipid depot facilitates the 
subsequent production of eicosanoid metabo-
lites, which play important roles in the regula-
tion of myocardial physiology, bioenergetics, 
contractile function, and signaling pathways 
[43]. Our earlier studies suggest that in mice, 
lipocalin-2 deficiency attenuates the metabo-
lism of arachidonic acid, which in turn allevi-
ates aging- and obesity-associated metabolic 
dysfunctions [10, 12]. In fact, the effects of 
lipocalin-2 on phospholipid remodeling may 
also explain the observations that lack of this 
protein in mice is associated with enhanced 
insulin sensitivity in both metabolic organs [12] 
and endothelial cells [16]. Insulin signaling de-
pends on inositol phospholipids, which recruit 
phosphoinositide 3-kinases (PI3K) to produce 
phosphatidylinositol(3,4,5)-triphosphate (PIP3) 
and activate the downstream signaling cas-
cades [44, 45]. The affinity of PI3K increases 
when the membrane phospholipids contain an 
arachidonoyl fatty acyl chain in the sn-2 posi-
tion [46]. In PI fraction of Lcn2-KO hearts, there 
is an elevated C20:4 content when compared 
to that in WT hearts. By alteration of the C20:4 
acyl composition in this type of phospholipids, 
lipocalin-2 may attenuate signaling evoked by 
insulin or other factors.  
 
The molecular events in lipocalin-2-induced 
phospholipids remodeling are not clear. It is not 
known whether this process is though a recep-
tor-mediated signaling cascade or depends on 
the lipid carrier property of this protein. Never-
theless, the selective regulation of C18:2 acyl 
chain by lipocalin-2 suggests the involvement 
of a more specific pathway in heart tissue. 
Since the enzymes responsible for de novo 
phospholipid synthesis do not exhibit acyl-
specificity, the 18:2-rich composition is mainly 
achieved via an acyl chain remodeling process 
[35]. Enzymes involved in the remodeling of 
acyl groups in phospholipids include phospholi-
pase A1, phospholipase A2, acyltransferases 
and transacylases, as well as tafazzin [47-49]. 
Whether lipocalin-2 regulates the activity of 
these enzymes is currently under investigation 
in our laboratory. In addition, lipocalin-2 may 
act as a lipid chaperone to selectively facilitate 
linoleic acid transportation into and translocali-
zation within cardiomyocyte. It may also pathol-
ogically remodel phospholipids and cardiolipin 
by oxidation through non-enzymatic (free-
radical mediated) or enzymatic (lipoxygenases 
or peroxidases) mechanisms. Moreover, the 
detailed cellular mechanisms contributing to 
the regulatory effects of lipocalin-2 on cardiac 
function remain to be addressed, such that 
whether this adipokine primarily acts on cardio-
myocytes or through vascular endothelium, or 
both at the same time. Conceptually, the ef-
fects of lipocalin-2 can be direct as well as indi-
rect, like other circulating adipokines/
hormones such as adiponectin. Phospholipid 
remodeling may represent a common mecha-
nism underlying lipocalin-2’s actions in vascula-
ture, heart, adipose tissues and others, and the 
involvement of cross-talks between these inter-
related organs cannot be excluded. Despite 
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these promises and gaps related to lipocalin-
2’s action, it is intriguing to speculate that re-
verse remodeling to restore functional phos-
pholipids pool of hearts by targeting lipocalin-2 
may represent a potential strategy to improve 
the cardiac mitochondrial function and to pre-
vent I/R injury. 
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Supporting Information 
 
Materials and Methods: 
Echocardiography. Echocardiographic studies were performed under light anesthesia and 
spontaneous respiration. The chest was shaved and warmed acoustic coupling gel was 
applied. Subsequently, mice were fixed supine in a left lateral position on a heated pad to 
keep the body temperature at 37°C. A Vivid i cardiovascular ultrasound system with a 
11.5 MHz probe (GE Healthcare, Milwaukee, WI) was used for the echocardiographic 
examination of cardiac structure and function. Echocardiographic parameters, including 
interventricular septum (IVS), left ventricular internal diameter (LVID), left ventricular 
posterior wall (LVPW), the long-axis percentage LV ejection fraction (EF) and 
percentage LV fractional shortening (FS) were recorded using M-mode measurement. 
The depth was set to 2 cm and zoomed to 1.2 cm. Wall thickness and LV dimensions 
were obtained from the parasternal long axis view at a frame rate of 260Hz. FS was 
calculated as FS(%)=[(LVIDd−LVIDs)/LVIDd)]×100, where LVIDd is LV internal 
dimension in diastole and LVIDs is LV internal dimension at end-systole. EF was 
calculated from the parasternal long-axis view using the equation 
EF(%)=[(LVAd−LVAs)/LVAd]×100.  
Heart preparation and perfusion. After injection of heparin (10,000 IU kg–1, i.p.), the 
hearts were excised and placed in ice-cold Krebs-Henseleit (KH) buffer solution (118 
mmol/L NaCl, 25 mmol/L NaHCO3, 4.7 mmol/L KCl, 1.2 mmol/L MgSO4, 1.2 mmol/L 
KH2PO4, 2.5 mmol/L CaCl2, and 11 mmol/L D-glucose, pH 7.4), which immediately 
stopped the contractile activity of the heart. The aorta was rapidly slipped onto a grooved 
20-gauge stainless steel cannula attached to the perfusion column, and retrograde 
perfusion initiated immediately with KH buffer oxygenated with 95% O2 and 5% CO2 at 
37°C at a constant perfusion pressure of 80 mmHg. The total time from heart excision to 
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initiation of Langendorff perfusion was less than 2 min. A polyethylene, fluid-filled 
balloon was introduced into the left ventricle (LV) cavity through the left atrial incision. 
The balloon catheter was linked to a pressure transducer connected to a data acquisition 
system for assessing LV contractile functions. The volume of the balloon was tested 
before insertion into the heart, and it was large enough to be inflated with 30 µL saline 
without producing a pressure of more than 1 mmHg. After insertion, the balloon was 
adjusted to obtain a LV end diastolic pressure (LVEDP) of 4–10 mmHg during the 
equilibration period. Heart rate (HR) was obtained from the LV pressure signal. Coronary 
flow (CF) was monitored by collection of the coronary effluent into pre-cooled tubes 
prior to ischemia and over each 5 min during reperfusion.  
I/R injury and cardiac function evaluation. Following a stabilization period of 30 min, 
the isolated hearts were subjected to either continuous perfusion for a further 80 min or a 
period of 20 min global ischemia followed by 60 min of reperfusion. Hearts were 
excluded from the protocol at the end of the stabilization period if they did not meet the 
inclusion criteria: HR > 300 beats min–1, 1.5 ml < CF < 5 mL min–1 and LV systolic 
pressure > 80 mmHg. Global ischemia was achieved by clamping the inflow tubing. 
During ischemia, the hearts were immersed in a 37 °C chamber to keep the temperature 
constant. Functional recoveries were recorded during reperfusion. The left ventricular 
systolic pressure (LVSP), LVEDP, HR and CF were monitored continuously. 
Rate-pressure product (RPP) was calculated as the product of LVDP 
(LVDP=LVSP-LVEDP) and HR using the formula (RPP=LVDP*HR/100). To assess the 
extent of myocardial tissue injury, 1 ml of effluent from the perfused heart was collected 
at 1, 5, 10, 20 and 30 min of reperfusion for measuring LDH activity by a biochemical 
analyzer (BS-120, Chemistry Analyzer, Midray, China). For infarct size analysis, after 
120 min of reperfusion, the hearts were snap-frozen and cut into 0.7 mm slices for 
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staining with 1% (w/v) 2,3,5-triphenyl-tetrazolium chloride (TTC, Sigma, St Louis, MO, 
USA) to aid visualization of the infarcted area. Digital images of heart sections were 
analyzed for LV area and infarct area (IA) using Image J software (National Institutes of 
Health).  
Chronic treatment with recombinant adenoviruses or acute treatment with lipocalin-2 
protein. The adenovirus vector encoding FLAG-tagged murine lipocalin-2 was generated 
using the Adeno-X Expression System (Clontech, Mountain View, CA). The 
recombinant adenovirus was injected into the tail vein of mice two weeks prior to tissue 
collection 1. The amount of injected adenovirus (108 plaque-forming units) caused no 
toxicity in the mice. The increased expression level of lipocalin-2 was confirmed by both 
Western blotting and enzyme linked immunosorbent assay as described 1. Recombinant 
murine lipocalin-2 was expressed, purified and endotoxin removed to less than 0.1 EU/ml 
1
. The purity of the protein was confirmed by SDS-PAGE and mass spectrometry analysis. 
No siderophore or iron was found to bind to the protein. Administration of lipocalin-2 
was performed by intraperitoneal injection (800 µg protein per mouse). Mice were 
sacrificed under anesthesia at different time points (0, 1, 2, 4, 6 and 12 hours) after 
injection for experiment.  
Electron microscopy analysis of mitochondrial ultrastructures. The electron 
micrographs and ultrathin sections were prepared from hearts freshly collected from WT 
and Lcn2-KO mice. Ultrastructural analysis was performed in the Electron Microscope 
Unit of our institution and examined by experienced electron microscopists blinded to the 
treatment groups. In brief, LV myocardium was cut to 1 mm3 and fixed with 2.5% 
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) for overnight at 4˚C. After brief 
washing, the specimens were postfixed in 1% osmium tetroxide, dehydrated, embedded 
in epoxy resin, and polymerized overnight at 60°C. Ultra-thin sections (100 nm) were cut 
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and poststained with Reynold’s lead citrate and uranyl acetate to increase contrast. 
Sections were viewed and photographed using a Philips EM208S transmission electron 
microscopy (TEM) (Eindhoven, The Netherlands).  
Measurement of mitochondrial respiratory chain (MRC) activities. Cardiomyocyte 
contains two distinct subpopulations of mitochondria, subsarcolemmal mitochondria 
(SSM) and interfibrillar mitochondria (IFM). Short period incubation of heart tissue with 
trypsin could facilitate the separation of IFM from the fibrillar 2. Here, the combined 
cardiac mitochondria fractions were isolated following the instruction of a commercial kit 
MITOISO1 (Sigma, St Louis, MO, USA) and the MRC activity of individual complex 
was evaluated as described 3. Briefly, freshly collected heart tissues were cut into small 
pieces and washed with extraction buffer (10 mM HEPES containing 200 mM manitol, 
70 mM sucrose and 1 mM EGTA, pH 7.5). After incubating with 0.25 mg/ml trypsin in 
extraction buffer on ice for 20-min, 10 mg/ml BSA was added to quench the proteolytic 
activities. The heart tissue suspensions were subsequently homogenized using a Dounce 
glass homogenizer and briefly centrifuged at 600 × g for 5 min. The supernatant was 
collected and centrifuged at 11,000 × g for 10 min. The pellet was suspended in storage 
buffer (10 mM HEPES, containing 250 mM sucrose, 1 mM ATP, 0.08 mM ADP, 5 mM 
sodium succinate, 2 mM K2HPO4 and 1 mM DTT). Preparations were used immediately 
for the assessment of MRC activity. The remainder of the samples was frozen at −80°C.  
Profiling and quantification of fatty acyl chains. For fatty acid composition analysis, the 
total and fractionated lipids were evaporated to dryness by nitrogen flow, and 
reconstituted in a mixture of 0.5 ml 4% methanolic HCl, 0.5 ml methanol and 125 µl 
hexane. After the addition of internal standard I [5 µl, 20 mg/ml nonadecanoic acid C19:0 
(Sigma)], the mixture was boiled at 100°C for 60 min and then mixed with 1ml hexane 
and 1 ml of deionized water. The upper layer was collected and the internal standard II [5 
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µl, 10 mg/ml tridecanoic acid methyl ester methyl C13:0 (Sigma)] added. Methyl esters 
were analyzed by gas chromatography-mass spectrometry (GC-MS) using a 6890N 
Network GC system attached to a 5973 Network Mass Selective Detector (Agilent, Palo 
Alto, CA, USA). The concentration of each fatty acid species was quantified by relating 
the peak area to those of the fatty acid standards (Supelco® 37 Component FAME mix, 
10 mg/ml). All results were normalized against the initial protein contents in each sample. 
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Supplementary Table 1. Evaluation of LV function by echocardiography1. 
Experimental groups HW/ 
BW% 
LVIDd LVIDs FS LVPWd LVPWs IVSd IVSs EF 
7-wk 
HF2 
WT 0.35± 
0.01 
3.74± 
0.43 
2.65± 
0.69 
29.17±
2.89  
0.68± 
0.10 
0.93± 
0.05 
0.76± 
0.05 
1.12±
0.19 
63.17±
3.32 
Lcn2-KO 0.35± 
0.02 
3.89± 
0.36 
2.60± 
0.38 
33.33±
2.20* 
0.65± 
0.09 
1.04± 
0.15 
0.75± 
0.08 
1.10±
0.15 
69.20±
3.66* 
16-wk 
STC3 
WT 0.52± 
0.04 
4.15± 
0.69 
2.78± 
0.76 
33.01±
2.37 
0.75± 
0.06 
1.10± 
0.16 
0.79± 
0.06 
1.27±
0.02  
68.67±
2.17 
Lcn2-KO 0.53± 
0.04 
3.75± 
0.26 
2.31± 
0.48 
38.66±
2.54* 
0.73± 
0.04 
1.02± 
0.19 
0.73± 
0.01 
1.14±
0.06 
73.00±
3.92* 
1Data are presented as means ± SEM, n = 12 animals/group. 
2Mice fed with high fat diet (HF) for seven weeks (starting from the age of 4-wk). 
3Mice (20-wk old) fed with standard chow (STC). 
*, P < 0.05 vs corresponding WT control group. 
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Supplementary Figure 1. Comparison of the mtDNA copy number and the mRNA expression of
genes regulating mitochondrial biogenesis. DNA was extracted from heart tissues of mice under
standard chow (NC) or high fat diet (HF). Gene copy number was measured as described in Method
(A). The expression of genes involved in mitochondrial biogenesis was evaluated by quantitative
PCR analysis (B). The results were expressed as fold change against the value of WT mice. *, P <
0.05; **, P < 0.01 vs WT, n = 5. mTFAM, mitochondrial transcription factor A; Polγ, mitochondrial
DNA polymerase gamma; PGC-1α, peroxisome proliferators-activated receptor gamma co-activator-
1α.
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Supplementary Figure 2. GC-MS analysis of the fatty acyl composition in four major types of cardiac
phospholipids. Heart tissues were collected from WT and Lcn2-KO mice after 7-wk of high fat diet.
Solid-phase extraction was performed to obtain phospholipids fractions, including PC, PE PI and PS.
Fatty acyl chain composition was analyzed using GC-MS. The compositions of fatty acyl chains in each
of the four types of phospholipids are presented for both WT (inside circle) and Lcn2-KO (outside circle)
samples, n = 4.
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Supplementary Figure 3. GC-MS analysis of the fatty acyl composition in cardiac phospholipids.
Heart tissues were collected from WT and Lcn2-KO mice after 7-wk of high fat diet. Solid-phase
extraction was performed to obtain four major fractions of phospholipids, PC, PE, PS and PI. Fatty
acyl chain composition was analyzed using GC-MS. The results were presented as the percent
distribution of each fatty acyl chain among the four types of phospholipids for both WT (inside circle)
and Lcn2-KO (outside circle) hearts, n = 4.
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Supplementary Figure 4. GC-MS analysis of the fatty acyl composition in cardiac mitochondrial
phospholipids. Heart mitochondria were prepared from WT and Lcn2-KO mice after 7-wk of high fat
diet, and subjected to phospholipids fractionation using the solid-phase extraction protocol described
in Methods. The four major fractions of phospholipids, PC, PE, PS and PI were subsequently
combined for fatty acyl chain composition analysis using GC-MS. The results were presented as the
percent distribution of each fatty acyl chain among the total phospholipids for both WT (inside circle)
and Lcn2-KO (outside circle) hearts, n = 4.
Supplementary Figure 5. Reversed-phase HPLC analysis of different cardiolipin species in heart
mitochondria isolated from WT mice, Lcn2-KO mice, or Lcn2-KO mice treated with lipocalin-2 as in
Figure 6. The elution profile is presented and the six distinct species of cardiolipin indicated as
numbers. Note that the elution profile of cardiolipin was not altered by vehicle treatment (data not
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shown). The fatty acyl compositions for the six species are: 1, (C18:2)2(C22:6)2; 2, (C18:2)3(C22:6)1;
3, (C18:2)4; 4, (C18:2)2(C18:1)1(C22:6)1; 5, (C18:2)3(C18:1)1 and 6, (C18:2)2(C18:1)2.
